Cardiology

There is no evidence that blood pressure lowering drugs increase the risk of cancer, according to a major new study.

An expert physician discusses the role of agents that reduce triglyceride levels and the potential on cardiovascular risk.

Dapagliflozin (Farxiga; AstraZeneca) demonstrated positive results in the phase 3 DAPA-CKD trial.

A discussion on which factors to consider when assessing the need for management/reduction of cardiovascular risk.

A key opinion leader discusses effective risk prevention measures and challenges to reducing adverse events. He also considers effective educational resources for self-care.

This article reviews the evolving therapeutic landscape for lowering LDL-C and cardiovascular risk, with an emphasis on the role of omega-3 fatty acids.

Empagliflozin (Jardiance; Eli Lilly) met the primary end point of a study for adults with heart failure with reduced ejection fraction with or without diabetes.

Azithromycin may be linked to a greater risk of cardiovascular death, according to a recent study.

A new study found increased plaque buildup levels in women with HIV who also suffered from persistent depression and stress.

Individuals recently diagnosed with type 2 diabetes were more likely to die from heart failure than any other cardiovascular disease, a study found.

This is the first regulatory approval for aspirin plus ticagrelor dual antiplatelet therapy for individuals with high cardiovascular risk but without prior instances of heart attack or stroke.

Researchers from the Mount Sinai COVID Informatics Center report improved survival rates in COVID patients treated with anticoagulants.

Women and older adults are underrepresented in clinical trials evaluating cholesterol medications, according to a new study published in JAMA Network Open.

Monitoring and controlling heart disease may be crucial in supporting cognitive health later in life.

A new study found that the use of PCSK9 inhibitors with maximally tolerated statins does not negatively affect the mental cognition of patients.

Results of the study showed that antihypertensive medications do not put individuals at increased risk for COVID-19.

Officials with the FDA have approved dapagliflozin (Farxiga, AstraZeneca) to reduce the risk of cardiovascular death and hospitalization in adults with heart failure with reduced ejection fraction, with and without type 2 diabetes.

Two new studies underscore health disparities in rural United States affecting mortality rates associated with cardiovascular disease.

Bempedoic acid (Nexletol, Esperion), an oral, once-daily, non-statin low-density lipoprotein-cholesterol lowering medicine, is now available in US pharmacies.

Ticagrelor alone, without aspirin, reduced bleeding without increasing the cardiovascular risks.

Alirocumab significantly reduced low-density lipoprotein cholesterol in adults with homozygous familial hypercholesterolemia, according to phase 3 data. 

Empagliflozin (Jardiance, Eli Lilly and Boehringer Ingelheim) is being investigated to reduce the risk of kidney disease progression and cardiovascular death in adults with chronic kidney disease.

Fish oil supplementation may be associated with lower all-cause mortality, cardiovascular disease (CVD) mortality, and CVD events.

A new study found several shortcomings in blood pressure management.

The differences between antihypertension medication classes were generally small and nuanced in terms of their effect on reducing cardiovascular risks.

A secondary analysis presented at the American Stroke Association’s International Stroke Conference 2020 confirmed the safety of apixaban treatment.

Bempedoic acid (Nexletol, Esperion) is a new lipid-lowering therapy option for patients with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease.

Rosiglitazone, which is used to treat type 2 diabetes, may increase the risk of heart problems.

A new study shows that patients who initiated treatment with blood pressure or cholesterol medications were more likely to reduce activity and gain weight.

SGLT2 inhibitor therapy provided protective effects from cardiovascular (CV) events in patients with type 2 diabetes with or without established CV disease.